Therapeutic Discovery
Targeted cancer treatment
Research & DevelopmentEarly stage research
Key Facts
Indication
Targeted cancer treatment
Phase
Research & Development
Status
Early stage research
Company
About bioAffinity Technologies
bioAffinity Technologies is dedicated to improving cancer outcomes through its proprietary porphyrin-based platform technology, which enables analysis of the lung microenvironment. The company's lead product, CyPath® Lung, has demonstrated high sensitivity and specificity in clinical studies for detecting early-stage lung cancer and is commercially available as an LDT. bioAffinity is actively expanding its platform to develop targeted diagnostics and therapeutics for other cancers and lung diseases, positioning itself at the intersection of precision diagnostics and cellular-level cancer treatment.
View full company profile